TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26908801
Drug: IIV-HD (High-Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: IIV-HD (High-Dose Inactivated Influenza Vaccine)
Study: 26908801
Drug: IIV-SD (Standard-Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: IIV-SD (Standard-Dose Inactivated Influenza Vaccine)
Study: 24131759
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg triamcinolone acetonide (single injection)
Study: 24131759
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg triamcinolone acetonide (repeat injection at 21-day interval)
Study: 24131759
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no corticosteroid injection)
Study: 10974832
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (total laryngectomy + postoperative RT)
Study: 8816612
Drug: Cabergoline (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabergoline (0.5 mg/wk)
Study: 3915460
Drug: Penbutolol 20
Normalized name: penbutolol 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penbutolol 20 mg + Piretanide 3 mg
Study: 3915460
Drug: Penbutolol 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penbutolol 40 mg + Piretanide 6 mg
Study: 27370
Drug: Penbutolol 20
Normalized name: penbutolol 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penbutolol 20 mg
Study: 27442637
Drug: Repeat transforaminal
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeat transforaminal epidural steroid injection (TFESI) at 2 to 3 weeks after the first injection
Study: 27442637
Drug: Intermittent transforaminal
Normalized name: transforming growth factor beta 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent transforaminal epidural steroid injection (TFESI) only for pain aggravation
Study: 19855315
Drug: Carbamazepine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbamazepine (100 mg three times daily for 7 days)
Study: 11570312
Drug: Monthly injectable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly injectable combination hormone contraceptive
Study: 9720517
Drug: UroPhos-K (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: UroPhos-K (4 tablets twice daily)
Study: 8147942
Drug: Promazine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Promazine (100 mg orally)
Study: 8147942
Drug: Chlorpromazine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpromazine (150 mg orally)
Study: 8147942
Drug: Promethazine (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Promethazine (75 mg orally)
Study: 8147942
Drug: Promazine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Promazine (20 mg intravenously)
Study: 8147942
Drug: Chlorpromazine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpromazine (50 mg intravenously)
Study: 8147942
Drug: Promethazine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Promethazine (50 mg intravenously)
Study: 2849461
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy with cisplatin (70 mg/m2) and etoposide (100 mg/m2), given every third week for a maximum of 4 cycles
Study: 3415853
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy with cisplatin and etoposide
Study: 28441699
Drug: Enalapril +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril + Folic Acid (10 mg enalapril and 0.8 mg folic acid)
Study: 28148501
Drug: Enalapril alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril alone (10 mg enalapril)
Study: 23846159
Drug: Beetroot juice
Normalized name: tamarind juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beetroot juice (BR) 70 mL
Study: 19715804
Drug: Intraperitoneal analgesic
Normalized name: ANALGESIC CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal analgesic (levobupivacaine 0.5%)
Study: 17021267
Drug: Intradialytic parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradialytic parenteral nutrition (IDPN)
Study: 11021270
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) and insulin-like growth factor-I (IGF-I) treatment
Study: 30844507
Drug: Intraoperative lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraoperative lidocaine infusion (1.5mg/kg bolus followed by 2 mg/kg/h)
Study: 30844507
Drug: Perioperative pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Perioperative pregabalin (300mg preoperatively, 75mg twice daily for 9 days)
Study: 2816761
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (10 mg)
Study: 7914736
Drug: Propofol combined
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol combined with alfentanil infusions
Study: 28241699
Drug: Ginaton in
Normalized name: Genaton
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginaton in addition to conventional treatment
Study: 26044447
Drug: Dia-Fit (web-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dia-Fit (web-based cognitive behaviour therapy)
Study: 17079638
Drug: Oral acetaminophen
Normalized name: acetaminophen Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral acetaminophen 30 mg x kg(‐1)
Study: 7621214
Drug: Topical 2%
Normalized name: menthol topical 2% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 2% lidocaine
Study: 5558187
Drug: Hospital treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hospital treatment initially in an intensive care unit
Study: 28595611
Drug: traditional clinic‐based
Approvals — FDA: no, EMA: no, PMDA: no
Description: traditional clinic‐based CI therapy
Study: 28595611
Drug: therapist‐as‐consultant video
Approvals — FDA: no, EMA: no, PMDA: no
Description: therapist‐as‐consultant video game CI therapy
Study: 28595611
Drug: therapist‐as‐consultant video
Approvals — FDA: no, EMA: no, PMDA: no
Description: therapist‐as‐consultant video game CI therapy with additional therapist contact via telerehabilitation/video consultation
Study: 27140799
Drug: Single 100-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 100-mg doses of migalastat HCl capsule
Study: 27140799
Drug: Single 100-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 100-mg doses of migalastat HCl capsules with a high-fat meal
Study: 27140799
Drug: Single 150-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 150-mg doses of migalastat HCl capsules with a high-fat or light meal
Study: 27140799
Drug: 50-g glucose
Normalized name: glucose 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50-g glucose drink co-administered with migalastat HCl
Study: 16769001
Drug: Metronidazole (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole (500 mg/i.v./8 h) + Gentamicin (5 mg/kg/i.v./24 h)
Study: 15330272
Drug: Plant sterol
Normalized name: plant sterol complex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plant sterol esters (1.6g daily)
Study: 15330272
Drug: Plant stanol
Normalized name: plant stanol ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plant stanol esters (1.6g daily)
Study: 15330272
Drug: Plant stanol
Normalized name: plant stanol ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plant stanol esters (2.6g daily)
Study: 4028281
Drug: Bacampicillin (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacampicillin (16 g/die)
Study: 4028281
Drug: Amoxicillin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin (2 g/die)
Study: 3280741
Drug: 5‐FU and
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐FU and FA (folinic acid), 200 mg/m2/d for five consecutive days along with 5‐FU, 370 mg/m2/d for five days
Study: 25463962
Drug: Alcohol dose
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol dose condition (BAC .05 or .08)
Study: 23850630
Drug: Cognitive behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behaviour therapy (CBT) program
Study: 21726496
Drug: oral ROF
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral ROF 500 μg q.d. on Days 6 - 10 in addition to oral THEO 375 mg b.i.d. on Days 1 - 10
Study: 21726496
Drug: oral ROF
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral ROF 500 μg q.d. on Days 1 - 5
Study: 21726496
Drug: oral THEO
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral THEO 375 mg b.i.d. on Days 1 - 10
Study: 17098656
Drug: SC group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC group (S): 10 mL of 0.25% bupivacaine and 10 mL of 0.9% saline
Study: 17098656
Drug: C group:
Approvals — FDA: no, EMA: no, PMDA: no
Description: C group: 10 mL of 0.25% bupivacaine (SF and SC)
Study: 16305006
Drug: Bleaching with
Normalized name: Dioxybenzone/Hydroquinone/Padimate O 30 MG/1 GM-40 MG/1 GM-50 MG/1 GM Topical application Gel/Jelly [HYDROQUINONE SKIN BLEACHING WITH SUNSCREENS]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bleaching with peroxide and light (exact dosage and duration not specified)
Study: 11575895
Drug: Long-acting bronchodilators
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting bronchodilators (LABD)
Study: 8174988
Drug: Loxiglumide (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loxiglumide (10 mg/kg/h)
Study: 7511552
Drug: Proton irradiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton irradiation as monotherapy (15 lesions)
Study: 7511552
Drug: Proton irradiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton irradiation as combination therapy with Lipiodol-targeted chemotherapy (17 lesions)
Study: 3203062
Drug: BN52063 (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: BN52063 (120 mg)
Study: 25198942
Drug: Tamsulosin 0.4
Normalized name: tamsulosin 0.4 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin 0.4 mg once daily (Group A)
Study: 25198942
Drug: Silodosin 8
Normalized name: silodosin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silodosin 8 mg once daily (Group B)
Study: 1528786
Drug: Chloral hydrate
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloral hydrate (CH) 50 mg/kg
Study: 23594140
Drug: Hydroxyzine HCL
Normalized name: hydroxyzine HCl
DrugBank: Hydroxyzine (DB00557)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxyzine HCL (HH) 1 mg/kg
Study: 21288233
Drug: Oral cholecalciferol
Normalized name: cholecalciferol Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cholecalciferol 2,000 IU daily for 6 months
Study: 11722961
Drug: Microencapsulated ferrous
Normalized name: Ferrous Fumarate
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Microencapsulated ferrous fumarate (80 mg elemental Fe) plus ascorbic acid (sprinkles group)
Study: 11722961
Drug: Ferrous sulfate
Normalized name: Ferrous Sulfate
DrugBank: Ferrous fumarate (DB14491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous sulfate drops (40 mg elemental Fe, administered 3 times/d for 2 months) (control group)
Study: 9465948
Drug: Guar with
Normalized name: Guar Gum
DrugBank: Guar gum (DB13446)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guar with iotrolan (11.2 mg iodine/ml)/guar (4 g/l) suspension
Study: 9465948
Drug: Aqueous solutions
Normalized name: Pen-Aqueous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqueous solutions of pure iotrolan (11.2 mg iodine/ml)
Study: 9465948
Drug: Meglumine ioxithalamate
Normalized name: meglumine ioxithalamate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meglumine ioxithalamate (12 mg iodine/ml)
Study: 8192515
Drug: Albendazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole (20 mg/kg/day) + Cimetidine (10 mg/kg/day)
Study: 8192515
Drug: Albendazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole (20 mg/kg/day)
Study: 3669497
Drug: Arginine HCl,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arginine HCl, 500 mg/kg
Study: 3669497
Drug: Arginine HCl,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arginine HCl, 200 mg/kg
Study: 8222513
Drug: D-glucose infusion
Normalized name: D-glucose
DrugBank: D-glucose (DB01914)
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-glucose infusion
Study: 30561539
Drug: Control vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control vaccine (Verorab)
Study: 26109581
Drug: Enteral infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enteral infusion of maltodextrins with protein powder (0.14 g proteins · kg⁻¹ · h⁻¹)
Study: 26109581
Drug: Maltodextrins alone
Normalized name: Maltodextrin
DrugBank: Maltodextrin (DB12583)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maltodextrins alone (0.25 g · kg⁻¹ · h⁻¹)
Study: 19643435
Drug: Echocardiographically directed
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Echocardiographically directed duration of indomethacin treatment (ECHO); 0.1 mg/kg
Study: 19643435
Drug: Standard treatment;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment; 0.1 mg/kg indomethacin, 2 more doses irrespective of echocardiographic findings
Study: 11719727
Drug: Fluvoxamine at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine at 0 mg/d
Study: 11719727
Drug: Fluvoxamine at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine at 25 mg/d
Study: 11719727
Drug: Fluvoxamine at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine at 75 mg/d
Study: 2844334
Drug: Intravenous foscarnet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous foscarnet
Study: 3294978
Drug: Nifedipine 30
Normalized name: nifedipine 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 30 mg/day for 4 weeks
Study: 26850076
Drug: Ibutilide (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibutilide (0.25 mg intravenous)
Study: 24142988
Drug: Exercise programme
Normalized name: Immunoglobulin G4, anti-programmed cell death protein 1 (PDCD1) (humanized clone ABT1 gamma4-chain), disulfide with humanized clone ABT1 kappa-chain, dimer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise programme (daily stretching exercise and twice-a-week muscle endurance training)
Study: 16100213
Drug: Etanercept, 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept, 25 mg subcutaneously twice a week
Study: 4096057
Drug: Daily training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily training programme during hospital stay
Study: 16514568
Drug: Wireless capsule
Normalized name: careless weed pollen extract
DrugBank: Amaranthus palmeri pollen (DB10459)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wireless capsule endoscopy
Study: 12477214
Drug: Usual treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual treatment plus a patient education program (Group B)
Study: 12477214
Drug: Usual treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual treatment (Group A)
Study: 12477214
Drug: Usual treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual treatment plus a patient education program (Group B) in moderate-to-severe asthma
Study: 9658727
Drug: Low-dose cyclophosphamide
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cyclophosphamide (1.5 g/m2 i.v. day 0) plus G-CSF (5 ug/kg/day s.c. from day +1 to end of leukapheresis)
Study: 9658727
Drug: Low-dose cyclophosphamide
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cyclophosphamide plus G-CSF
Study: 8294680
Drug: Sequential defibrillation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential defibrillation alone
Study: 8294680
Drug: Combined biphasic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined biphasic plus sequential defibrillation
Study: 2962947
Drug: Yeast-derived hepatitis
Normalized name: YEAST CELL,LIVE DERIVATIVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yeast-derived hepatitis B vaccines (partially purified or highly purified)
Study: 2962947
Drug: Plasma-derived hepatitis
Normalized name: Haptoglobulin 1/1 (Plasma Derived)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma-derived hepatitis B vaccine (control)
Study: 30089607
Drug: Therapist-assisted Internet-Based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapist-assisted Internet-Based Cognitive Behavioral Therapy (iCBT)
Study: 28162905
Drug: Bilateral arm
Normalized name: ARM-210
DrugBank: ARM-210 (DB16944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral arm training (30 minutes, additional to general occupational therapy)
Study: 28162905
Drug: General occupational
Approvals — FDA: no, EMA: no, PMDA: no
Description: General occupational therapy (30 minutes)
Study: 26591678
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium (medication group)
Study: 21540753
Drug: Combined exercise
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined exercise training (EX) - concurrent circuit resistance exercise (RE) followed by endurance exercise (EE) at 60% of predicted maximal heart rate, 3 days per week
Study: 18344729
Drug: Venlafaxine 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine 300 mg/d
Study: 14533211
Drug: 24 hourly
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 hourly change of closed suction catheter (CSC)
Study: 14533211
Drug: 48 hourly
Approvals — FDA: no, EMA: no, PMDA: no
Description: 48 hourly change of closed suction catheter (CSC)
Study: 10761291
Drug: Administration of
Normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of ATC during PPV
Study: 3709614
Drug: Lorazepam 2
Normalized name: lorazepam 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam 2 mg (single and multiple doses)
Study: 3709614
Drug: Alprazolam 0.5
Normalized name: alprazolam 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam 0.5 mg (single dose)
Study: 3709614
Drug: Both drugs
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both drugs (single and multiple doses)
Study: 30878630
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose tigecycline (100 mg q12h)
Study: 30878630
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose tigecycline (50 mg q12h)
Study: 29481447
Drug: Photobiomodulation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photobiomodulation therapy with 30 J
Study: 29481447
Drug: Photobiomodulation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photobiomodulation therapy with 15 J
Study: 29481447
Drug: Photobiomodulation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photobiomodulation therapy with 60 J
Study: 22178762
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy plus a psychoeducational group intervention on alcohol drinking related to stress and trauma (PAST)
Study: 22147444
Drug: Rituximab (375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (375 mg/m²/week for 4 weeks)
Study: 20647198
Drug: Intravenous cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cyclophosphamide for 3 to 6 months followed by azathioprine
Study: 12061197
Drug: Icodextrin-based dialysis
Normalized name: Icodextrin Peritoneal Dialysis Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Icodextrin-based dialysis solution
Study: 12061197
Drug: Glucose-based dialysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose-based dialysis solution
Study: 10363074
Drug: ketorolac 10
Normalized name: ketorolac 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ketorolac 10 mg p.o. (t.i.d.)
Study: 10363074
Drug: diclofenac 50
Normalized name: DICLOFENAC 50MG/MISOPROSTOL 200MCG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: diclofenac 50 mg p.o. (t.i.d.)
Study: 2202655
Drug: 0.5% idoxuridine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% idoxuridine cream
Study: 2202655
Drug: 0.25% idoxuridine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25% idoxuridine cream
Study: 31925601
Drug: adapted parent‐child
Approvals — FDA: no, EMA: no, PMDA: no
Description: adapted parent‐child interaction therapy intervention with foster‐parent child dyads
Study: 31925601
Drug: multiple evidence-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: multiple evidence-based treatments (EBTs)
Study: 25909422
Drug: Silver sulfadiazine
Normalized name: Silver Sulfadiazine
DrugBank: Silver sulfadiazine (DB05245)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silver sulfadiazine (SSD) applied daily (n = 82)
Study: 17234675
Drug: EMLA cream
Normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMLA cream (lidocaine 25 mg-prilocaine 25 mg/G) applied to the uterine cervix 30 min before HSG
Study: 17234675
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream applied to the uterine cervix 30 min before HSG
Study: 7855193
Drug: Alcohol group
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol group A (0.62 g/kg) with withholding knowledge of results (KR)
Study: 7855193
Drug: Alcohol group
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol group AM (0.62 g/kg) with incentive for nonimpaired performance
Study: 27965882
Drug: Optimal Personalised
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal Personalised Care After Treatment for Gynaecological cancer (OPCAT-G) intervention
Study: 25211663
Drug: HER2/neu positive
Approvals — FDA: no, EMA: no, PMDA: no
Description: HER2/neu positive status in sigmoideal and rectal carcinomas
Study: 21807750
Drug: Waiting-list control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waiting-list control condition receiving treatment as usual
Study: 19001323
Drug: Consolidation docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Consolidation docetaxel 75 mg/m2 IV every 21 days for three cycles
Study: 16430387
Drug: Pill counting
Normalized name: Pill Counting Tray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pill counting
Study: 1673478
Drug: Nicardipine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine (30 mcg.kg‐1)
Study: 1673478
Drug: Verapamil (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (50 mcg.kg‐1)
Study: 1673478
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no Ca entry blocker)